{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:59:07Z","timestamp":1789556347721,"version":"build-2803163510"},"reference-count":42,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR301136"],"award-info":[{"award-number":["NIHR301136"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Qual"],"accepted":{"date-parts":[[2025,3,31]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Aminoglycoside antibiotics cause ototoxicity for which baseline audiometric testing is recommended but often not done. Barriers to successful implementation include limited availability of sound-booths and audiologists. An ototoxicity monitoring programme (OMP) was implemented using tablet-based audiometry (TBA) by non-audiologists.<\/jats:p>\n               <jats:p>A quality improvement project conducted over 1 year (19 April 2021 to 18 April 2022), using Plan Do Study Act (PDSA) cycles, monitored the adherence to the OMP using Shoebox Standard Edition application on iPads. Barriers to adoption were identified to determine potential solutions for improved adherence. Adult respiratory patients (cystic fibrosis (CF), bronchiectasis, non-tuberculosis mycobacteria (NTM) infection) aged 17\u201382 years receiving &gt;1 day of intravenous aminoglycosides (IVAGs) at a single tertiary-referral hospital were included. Other reported outcomes were patient characteristics, risk factors associated with abnormal hearing and ototoxic shift.<\/jats:p>\n               <jats:p>73 patients were tested in the OMP (46 received \u22652 hearing tests) giving an overall adherence rate of 69% after 12 months. Patient identification using referral and reporting systems initially improved adherence from 36% to 88% (p=0.03) during PDSA 1. Barriers to successful adherence were staff availability and COVID-19 infection outbreaks (p=0.057). Older age (p&lt;0.001), higher Body Mass Index (p=0.041), non-CF bronchiectasis (p=0.01), non-CF NTM (p=0.028) and higher Hearing Handicap Inventory for Adults scores (p=0.002) were significantly associated with abnormal baseline hearing. 78% with hearing loss were asymptomatic. Ototoxic shift was associated with gentamicin use compared to amikacin\/tobramycin (p=0.027). TBA was associated with high usability in patients \u226450 years old.<\/jats:p>\n               <jats:p>TBA by non-audiologists was feasible and demonstrated good patient usability, permitting screening of patients within 72 hours of starting IVAG and earlier referrals for formal audiometry. Hearing loss and ototoxicity were detected at earlier stages, enabling more rapid decision-making and treatment modification.<\/jats:p>","DOI":"10.1136\/bmjoq-2024-002847","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T16:30:26Z","timestamp":1744734626000},"page":"e002847","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Improving ototoxicity monitoring in patients receiving aminoglycosides using a novel digital approach: a quality improvement project"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4299-101X","authenticated-orcid":false,"given":"Jamie","family":"Cheong","sequence":"first","affiliation":[{"name":"Royal Brompton Hospital, London, UK"},{"name":"Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Boreland","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Shattock","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Bowman","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Belkarty","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jones","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imogen","family":"Felton","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emem-Fong","family":"Ukor","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Stowell","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo J","family":"Jose","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, UK"},{"name":"Centre for Inflammation and Tissue Repair, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Madge","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Wilkins","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Frost","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Presanna","family":"Premachandra","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas\u2019 NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Loebinger","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, UK"},{"name":"Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J","family":"Simmonds","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, UK"},{"name":"Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Drobniewski","sequence":"additional","affiliation":[{"name":"Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Shah","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, UK"},{"name":"Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"2025083113115942000_14.2.e002847.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200812-1845PP"},{"key":"2025083113115942000_14.2.e002847.2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-209729"},{"key":"2025083113115942000_14.2.e002847.3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur Respir J"},{"key":"2025083113115942000_14.2.e002847.4","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/14992027.2018.1514537","article-title":"Negative hearing effects of a single course of IV aminoglycoside therapy in cystic fibrosis patients","volume":"57","author":"Gleser","year":"2018","journal-title":"Int J Audiol"},{"key":"2025083113115942000_14.2.e002847.5","doi-asserted-by":"crossref","unstructured":"Jiang M , Karasawa T , Steyger PS . Aminoglycoside-Induced Cochleotoxicity: A Review. 11. Frontiers Media S.A, 2017.","DOI":"10.3389\/fncel.2017.00308"},{"key":"2025083113115942000_14.2.e002847.6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.7874\/jao.2017.00360","article-title":"Ototoxicity: A Challenge in Diagnosis and Treatment","volume":"22","author":"Ganesan","year":"2018","journal-title":"J Audiol Otol"},{"key":"2025083113115942000_14.2.e002847.7","doi-asserted-by":"publisher","DOI":"10.1097\/00003446-199406000-00004"},{"key":"2025083113115942000_14.2.e002847.8","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2214-109X(23)00514-4","article-title":"Priorities for hearing loss prevention and estimates of global cause-specific burdens of hearing loss: a systematic rapid review","volume":"12","author":"Prasad","year":"2024","journal-title":"Lancet Glob Health"},{"key":"2025083113115942000_14.2.e002847.9","doi-asserted-by":"publisher","DOI":"10.1080\/14992027.2021.1883197"},{"key":"2025083113115942000_14.2.e002847.10","first-page":"11","article-title":"Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy","volume":"36","year":"1994","journal-title":"ASHA"},{"key":"2025083113115942000_14.2.e002847.11","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1080\/14992027.2018.1460495","article-title":"Current practice of ototoxicity management across the United Kingdom (UK)","volume":"57","author":"Maru","year":"2018","journal-title":"Int J Audiol"},{"key":"2025083113115942000_14.2.e002847.12","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.02980"},{"key":"2025083113115942000_14.2.e002847.13","first-page":"S3","volume-title":"Applying U.S. National Guidelines for Ototoxicity Monitoring in Adult Patients: Perspectives on Patient Populations, Service Gaps, Barriers and Solutions","volume":"57","author":"Konrad-Martin","year":"2018"},{"key":"2025083113115942000_14.2.e002847.14","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1044\/2021_AJA-21-00031","article-title":"Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis","volume":"30","author":"Garinis","year":"2021","journal-title":"Am J Audiol"},{"key":"2025083113115942000_14.2.e002847.15","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22974"},{"key":"2025083113115942000_14.2.e002847.16","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1080\/14992027.2017.1370138","article-title":"Using tablet-based technology to deliver time-efficient ototoxicity monitoring","volume":"57","author":"Brungart","year":"2018","journal-title":"Int J Audiol"},{"key":"2025083113115942000_14.2.e002847.17","first-page":"1814","volume-title":"Pharmacist-Administered Audiology Screening for Pediatric Cystic Fibrosis Patients Exposed to High-Dose Aminoglycosides: A Pilot Study","volume":"57","author":"McKinzie","year":"2022"},{"key":"2025083113115942000_14.2.e002847.18","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-214177"},{"key":"2025083113115942000_14.2.e002847.19","unstructured":"Action on Hearing Loss. Hearing Matters, 2015."},{"key":"2025083113115942000_14.2.e002847.20","first-page":"279","volume-title":"Use the PDSA Model for Effective Change Management","volume":"26","author":"Donnelly","year":"2015"},{"key":"2025083113115942000_14.2.e002847.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs-2015-004411"},{"key":"2025083113115942000_14.2.e002847.22","doi-asserted-by":"publisher","DOI":"10.1097\/00003446-199012000-00004"},{"key":"2025083113115942000_14.2.e002847.23","doi-asserted-by":"publisher","DOI":"10.1097\/00003446-198205000-00006"},{"key":"2025083113115942000_14.2.e002847.24","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1996.01890140029007"},{"key":"2025083113115942000_14.2.e002847.25","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1990.01870040046011"},{"key":"2025083113115942000_14.2.e002847.26","doi-asserted-by":"publisher","DOI":"10.1177\/000348949710600305"},{"key":"2025083113115942000_14.2.e002847.27","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2273.2001.00490.x"},{"key":"2025083113115942000_14.2.e002847.28","doi-asserted-by":"publisher","DOI":"10.1097\/00129492-200403000-00010"},{"key":"2025083113115942000_14.2.e002847.29","unstructured":"Brooke J . SUS A\"quick and Dirty\" Usability Scale. London: Taylor & Francis, 1996:189\u201394."},{"key":"2025083113115942000_14.2.e002847.30","doi-asserted-by":"crossref","unstructured":"Shteinberg M , Taylor-Cousar JL . Impact of CFTR Modulator Use on Outcomes in People with Severe Cystic Fibrosis Lung Disease. 29. European Respiratory Review. European Respiratory Society, 2020.","DOI":"10.1183\/16000617.0112-2019"},{"key":"2025083113115942000_14.2.e002847.31","doi-asserted-by":"publisher","DOI":"10.1080\/10447310802205776"},{"key":"2025083113115942000_14.2.e002847.32","doi-asserted-by":"publisher","DOI":"10.1044\/2020_AJA-20-00059"},{"key":"2025083113115942000_14.2.e002847.33","doi-asserted-by":"crossref","unstructured":"Eckert MA , Harris KC , Lang H , et al . Translational and Interdisciplinary Insights into Presbyacusis: A Multidimensional Disease. 402. Hearing Research. Elsevier B.V, 2021.","DOI":"10.1016\/j.heares.2020.108109"},{"key":"2025083113115942000_14.2.e002847.34","unstructured":"Lethbridge-\u00c7ejku M , Schiller J , Bernadel L . Summary health statistics for U.S. Adults: National Health Interview Survey. 2002."},{"key":"2025083113115942000_14.2.e002847.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-021-01035-6"},{"key":"2025083113115942000_14.2.e002847.36","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jcf.2020.11.020","article-title":"Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment","volume":"20","author":"Harruff","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2025083113115942000_14.2.e002847.37","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jcf.2020.07.001","article-title":"Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin","volume":"20","author":"Garinis","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2025083113115942000_14.2.e002847.38","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s10162-002-2036-8","article-title":"Distribution of Gentamicin in the Guinea Pig Inner Ear after Local or Systemic Application","volume":"4","author":"Imamura","year":"2003","journal-title":"JARO - Journal of the Association for Research in Otolaryngology"},{"key":"2025083113115942000_14.2.e002847.39","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/147323000203000407","article-title":"Comparative cochlear toxicities of streptomycin, gentamicin, amikacin and netilmicin in guinea-pigs","volume":"30","author":"Kalkandelen","year":"2002","journal-title":"J Int Med Res"},{"key":"2025083113115942000_14.2.e002847.40","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3349\/ymj.2003.44.3.517","article-title":"comparative vestibultoxicity of different AG in guinea pigs","volume":"44","author":"Selimoglu","year":"2003","journal-title":"Yonsei Med J"},{"key":"2025083113115942000_14.2.e002847.41","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)17906-9","article-title":"Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis\u2014the TOPIC study: a randomised controlled trial","volume":"365","author":"Smyth","year":"2005","journal-title":"The Lancet"},{"key":"2025083113115942000_14.2.e002847.42","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr221"}],"container-title":["BMJ Open Quality"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjoq-2024-002847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T20:12:09Z","timestamp":1756671129000},"score":1,"resource":{"primary":{"URL":"https:\/\/qir.bmj.com\/lookup\/doi\/10.1136\/bmjoq-2024-002847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4,15]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bmjoq-2024-002847"],"URL":"https:\/\/doi.org\/10.1136\/bmjoq-2024-002847","relation":{},"ISSN":["2399-6641"],"issn-type":[{"value":"2399-6641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}